Cardiac resynchronization therapy: Part 1--issues before device implantation.

Relationship of echocardiographic dyssynchrony to long-term survival after cardiac resynchronization therapy. Circulation (2010) 1.87

Recent advances in cardiac resynchronization therapy: echocardiographic modalities, patient selection, optimization, non-responders--all you need to know for more efficient CRT. Int J Cardiovasc Imaging (2009) 1.51

Development and validation of a clinical index to predict survival after cardiac resynchronisation therapy. Heart (2009) 1.49

Repeatability and reproducibility of phase analysis of gated single-photon emission computed tomography myocardial perfusion imaging used to quantify cardiac dyssynchrony. Nucl Med Commun (2008) 1.33

Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts. Circ Cardiovasc Genet (2009) 1.32

Effects of biventricular pacing and scar size in a computational model of the failing heart with left bundle branch block. Med Image Anal (2008) 1.20

Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchronization therapy. Eur Heart J (2010) 1.20

Doppler echocardiography and myocardial dyssynchrony: a practical update of old and new ultrasound technologies. Cardiovasc Ultrasound (2007) 1.19

Imaging in cardiac resynchronisation therapy. Neth Heart J (2008) 1.15

Optimal left ventricular lead position assessed with phase analysis on gated myocardial perfusion SPECT. Eur J Nucl Med Mol Imaging (2010) 1.14

Prevalence and predictors of mechanical dyssynchrony as defined by phase analysis in patients with left ventricular dysfunction undergoing gated SPECT myocardial perfusion imaging. J Nucl Cardiol (2010) 1.14

Temporal resolution of multiharmonic phase analysis of ECG-gated myocardial perfusion SPECT studies. J Nucl Cardiol (2008) 1.13

Real-time three-dimensional echocardiography as a novel approach to quantify left ventricular dyssynchrony: a comparison study with phase analysis of gated myocardial perfusion single photon emission computed tomography. J Am Soc Echocardiogr (2008) 1.06

Cardiac resynchronization: insight from experimental and computational models. Prog Biophys Mol Biol (2008) 1.05

What is treatment success in cardiac resynchronization therapy? Europace (2009) 1.02

Echocardiographic speckle tracking radial strain imaging to assess ventricular dyssynchrony in a pacing model of resynchronization therapy. J Am Soc Echocardiogr (2008) 1.01

Feature tracking measurement of dyssynchrony from cardiovascular magnetic resonance cine acquisitions: comparison with echocardiographic speckle tracking. J Cardiovasc Magn Reson (2013) 1.00

Tissue synchronisation imaging accurately measures left ventricular dyssynchrony and predicts response to cardiac resynchronisation therapy. Heart (2007) 0.99

Optimal use of echocardiography in cardiac resynchronisation therapy. Heart (2007) 0.93

Evaluation of mechanical dyssynchrony and myocardial perfusion using phase analysis of gated SPECT imaging in patients with left ventricular dysfunction. J Nucl Cardiol (2008) 0.92

Temporary biventricular pacing decreases the vasoactive-inotropic score after cardiac surgery: a substudy of a randomized clinical trial. J Thorac Cardiovasc Surg (2012) 0.89

Reverse remodelling in heart failure with cardiac resynchronisation therapy. Heart (2006) 0.86

Quantitative analysis of intraventricular dyssynchrony using wall thickness by multidetector computed tomography. JACC Cardiovasc Imaging (2008) 0.85

Baseline tissue Doppler imaging-derived echocardiographic parameters and left ventricle reverse remodelling following cardiac resynchronization therapy introduction. Arch Med Sci (2011) 0.85

Method to create regional mechanical dyssynchrony maps from short-axis cine steady-state free-precession images. J Magn Reson Imaging (2013) 0.85

Hemodynamic stability during biventricular pacing after cardiopulmonary bypass. J Cardiothorac Vasc Anesth (2011) 0.84

Prevalence and pathophysiologic attributes of ventricular dyssynchrony in arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol (2009) 0.84

Imaging techniques in cardiac resynchronization therapy. Int J Cardiovasc Imaging (2007) 0.83

Use of phase analysis of gated SPECT perfusion imaging to quantify dyssynchrony in patients with mild-to-moderate left ventricular dysfunction. J Nucl Cardiol (2009) 0.83

Nonechocardiographic imaging in evaluation for cardiac resynchronization therapy. Circ Cardiovasc Imaging (2011) 0.82

Ultrafast assessment of left ventricular dyssynchrony from nuclear myocardial perfusion imaging on a new high-speed gamma camera. Eur J Nucl Med Mol Imaging (2010) 0.82

Clinical implication of mechanical dyssynchrony in heart failure. J Cardiovasc Ultrasound (2012) 0.81

Management of patients with non-ischaemic cardiomyopathy. Heart (2007) 0.81

Myocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Trial. Am Heart J (2009) 0.81

Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Heart Rhythm (2014) 0.81

Baseline vectorcardiography as a predictor of invasively determined acute hemodynamic response to cardiac resynchronization therapy. Clin Res Cardiol (2012) 0.80

A practical approach to imaging dyssynchrony for cardiac resynchronization therapy. Heart Fail Rev (2011) 0.80

Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur Heart J (2009) 0.80

Relation between three-dimensional echocardiography derived left ventricular volume and MRI derived circumferential strain in patients eligible for cardiac resynchronization therapy. Int J Cardiovasc Imaging (2008) 0.80

Ventricular resynchronization is the principle mechanism of benefit with cardiac resynchronization therapy. Heart Fail Rev (2012) 0.80

Relationship between mechanical dyssynchrony and intra-operative electrical delay times in patients undergoing cardiac resynchronization therapy. J Cardiovasc Magn Reson (2014) 0.79

Long-term outcome of patients with and without super-response to CRT-D. Clin Res Cardiol (2015) 0.79

Functional mitral regurgitation: a 30-year unresolved surgical journey from valve replacement to complex valve repairs. Heart Fail Rev (2014) 0.79

Role of cardiac MRI and nuclear imaging in cardiac resynchronization therapy. Nat Rev Cardiol (2009) 0.78

Relation of QRS shortening to cardiac output during temporary resynchronization therapy after cardiac surgery. ASAIO J (2010) 0.78

Can cardiac resynchronization therapy cause harm? Eur Heart J (2012) 0.77

Measuring mechanical function in the failing heart. J Electrocardiol (2006) 0.77

Measurement of QRS duration for biventricular pacing optimization. ASAIO J (2008) 0.77

Is cardiac resynchronisation therapy proarrhythmic? Indian Pacing Electrophysiol J (2008) 0.77

Imaging for planning of cardiac resynchronization therapy. JACC Cardiovasc Imaging (2012) 0.77

Utility of three-dimensional echocardiography in assessing and predicting response to cardiac resynchronization therapy. Can J Cardiol (2010) 0.76

Nuclear medicine in the management of patients with heart failure: guidance from an expert panel of the International Atomic Energy Agency (IAEA). Nucl Med Commun (2014) 0.75

Should mechanical dyssynchrony be assessed in patients with implantable cardioverter-defibrillators? J Nucl Cardiol (2010) 0.75

Monitoring of CRT-D devices during radiation therapy in vitro. Biomed Eng Online (2016) 0.75

Incremental value of cystatin C over conventional renal metrics for predicting clinical response and outcomes in cardiac resynchronization therapy: The BIOCRT study. Int J Cardiol (2015) 0.75

Potential uses of computed tomography for management of heart failure patients with dyssynchrony. Crit Pathw Cardiol (2008) 0.75

Normal and shear strains of the left ventricle in healthy human subjects measured by two-dimensional speckle tracking echocardiography. Cardiovasc Ultrasound (2014) 0.75

Does biventricular pacing improve hemodynamics in children undergoing routine congenital heart surgery? Pediatr Cardiol (2010) 0.75

Cardiac resynchronization therapy in clinical practice: need for electrical, mechanical, clinical and logistic synchronization. J Interv Card Electrophysiol (2007) 0.75

[Cardiac resynchronization therapy: preoperative screening. How can we reliably predict response to CRT?]. Herzschrittmacherther Elektrophysiol (2009) 0.75

Lack of clinical predictors of optimal V-V delay in patients with cardiac resynchronization devices. J Interv Card Electrophysiol (2009) 0.75

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36

Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18

Cardiac resynchronization in chronic heart failure. N Engl J Med (2002) 17.52

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J (2009) 11.90

Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr (2003) 11.88

Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J (2014) 9.73

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation (2008) 8.94

Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85

Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74

Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med (2015) 8.70

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75

Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35

Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation (2008) 7.11

ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol (2008) 6.78

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J (2013) 6.17

Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol (2005) 5.39

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol (2009) 5.35

Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA (2013) 5.31

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J (2013) 5.23

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21

Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation (2008) 5.15

Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med (2008) 5.13

ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J (2011) 5.11

Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med (2008) 4.64

ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation (2002) 4.56

Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation (2003) 4.51

Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50

ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48

A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med (2002) 4.42

Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm (2005) 4.39

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (2011) 4.36

Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet (2003) 4.21

Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J (2007) 4.15

2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace (2013) 4.07

Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace (2009) 3.90

ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation (2002) 3.89

Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol (2004) 3.87

Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med (2005) 3.83

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J (2016) 3.83

Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78

Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol (2002) 3.77

Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation (2008) 3.54

Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation (2006) 3.50

Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47

The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg (2007) 3.45

Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40

Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery: a randomized trial. JAMA (2010) 3.39

Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34

Novel speckle-tracking radial strain from routine black-and-white echocardiographic images to quantify dyssynchrony and predict response to cardiac resynchronization therapy. Circulation (2006) 3.29

Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA (2003) 3.25

2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2012) 3.25

Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest (2005) 3.22

Invasive hemodynamic characteristics of low gradient severe aortic stenosis despite preserved ejection fraction. J Am Coll Cardiol (2013) 3.19

Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol (2007) 3.16

A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. Eur Heart J (2011) 3.14

Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation (2006) 3.12

Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. Ann Intern Med (2013) 3.08

Evidence of structural remodeling in the dyssynchronous failing heart. Circ Res (2005) 3.05

Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol (2013) 3.03

Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01

Left bundle-branch block induced by transcatheter aortic valve implantation increases risk of death. Circulation (2012) 2.95

Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation (2005) 2.94

Tackling heart failure in the twenty-first century. Nature (2008) 2.93

Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. Eur Heart J (2007) 2.92

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2016) 2.91

Systolic improvement and mechanical resynchronization does not require electrical synchrony in the dilated failing heart with left bundle-branch block. Circulation (2002) 2.88

Left ventricular resynchronization is mandatory for response to cardiac resynchronization therapy: analysis in patients with echocardiographic evidence of left ventricular dyssynchrony at baseline. Circulation (2007) 2.85

Can LV dyssynchrony as assessed with phase analysis on gated myocardial perfusion SPECT predict response to CRT? J Nucl Med (2007) 2.82

Forced alignment of mesenchymal stem cells undergoing cardiomyogenic differentiation affects functional integration with cardiomyocyte cultures. Circ Res (2008) 2.80

TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol (2011) 2.78

ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm (2008) 2.75

Optimal left ventricular lead position predicts reverse remodeling and survival after cardiac resynchronization therapy. J Am Coll Cardiol (2008) 2.75

Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. J Am Soc Echocardiogr (2013) 2.71

Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation (2006) 2.69

Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy. J Am Coll Cardiol (2010) 2.66